The Promoting Role of HK II in Tumor Development and the Research Progress of Its Inhibitors-Reference-Cited by-同舟云学术

The Promoting Role of HK II in Tumor Development and the Research Progress of Its Inhibitors

Published:2023-12-22 Issue:1 Volume:29 Page:75
ISSN:1420-3049
Container-title:Molecules
language:en
Short-container-title:Molecules

Author:

Liu Bingru¹²,Lu Yu¹²³^ORCID,Taledaohan Ayijiang¹²,Qiao Shi⁴,Li Qingyan⁴,Wang Yuji¹²³^ORCID

Affiliation:

1. Department of Medicinal Chemistry, College of Pharmaceutical Sciences of Capital Medical University, Beijing 100069, China

2. Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Beijing Laboratory of Biomedical Materials, Laboratory for Clinical Medicine, Capital Medical University, Beijing 100069, China

3. Department of Core Facility Center, Capital Medical University, Beijing 100069, China

4. Civil Aviation Medical Center, Civil Aviation Administration of China, Beijing 100123, China

Abstract

Increased glycolysis is a key characteristic of malignant cells that contributes to their high proliferation rates and ability to develop drug resistance. The glycolysis rate-limiting enzyme hexokinase II (HK II) is overexpressed in most tumor cells and significantly affects tumor development. This paper examines the structure of HK II and the specific biological factors that influence its role in tumor development, as well as the potential of HK II inhibitors in antitumor therapy. Furthermore, we identify and discuss the inhibitors of HK II that have been reported in the literature.

Funder

Beijing Municipal Colleges and Universities High-Level Talents Introduction and Cultivate Project-Beijing Great Wall Scholar Program

Publisher

MDPI AG

Subject

Chemistry (miscellaneous),Analytical Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Molecular Medicine,Drug Discovery,Pharmaceutical Science

Link

https://www.mdpi.com/1420-3049/29/1/75/pdf

Reference193 articles.

1. Cancer statistics in China, 2016;Zheng;Zhonghua Zhong Liu Za Zhi,2023

2. Cancer statistics;Siegel;CA Cancer J. Clin.,2023

3. Dual or multi-targeting inhibitors: The next generation anticancer agents;Raghavendra;Eur. J. Med. Chem.,2018

4. Designing multi-targeted agents: An emerging anticancer drug discovery paradigm;Fu;Eur. J. Med. Chem.,2017

5. Multi-Targeting Anticancer Agents: Rational Approaches, Synthetic Routes and Structure Activity Relationship;Singh;Anti-Cancer Agents Med. Chem.,2019